WO2019078663A3 - 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 - Google Patents

아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2019078663A3
WO2019078663A3 PCT/KR2018/012392 KR2018012392W WO2019078663A3 WO 2019078663 A3 WO2019078663 A3 WO 2019078663A3 KR 2018012392 W KR2018012392 W KR 2018012392W WO 2019078663 A3 WO2019078663 A3 WO 2019078663A3
Authority
WO
WIPO (PCT)
Prior art keywords
hispro
cyclo
preventing
pharmaceutical composition
active ingredients
Prior art date
Application number
PCT/KR2018/012392
Other languages
English (en)
French (fr)
Other versions
WO2019078663A2 (ko
Inventor
정회윤
전종수
김보배
이헌종
송문기
이도현
Original Assignee
주식회사 노브메타파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 노브메타파마 filed Critical 주식회사 노브메타파마
Priority to US16/757,575 priority Critical patent/US11607441B2/en
Priority to EP18867498.0A priority patent/EP3698801A4/en
Priority to CN201880068309.0A priority patent/CN111246859B/zh
Priority to JP2020522310A priority patent/JP7005050B2/ja
Publication of WO2019078663A2 publication Critical patent/WO2019078663A2/ko
Publication of WO2019078663A3 publication Critical patent/WO2019078663A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본 발명은 (a) 아연 양이온과 음이온을 포함하는 아연염 및 시클로-히스프로, 또는 이의 약학적으로 허용 가능한 염; 및 (b) 항당뇨 약물(특히, 인슐린 감작제(insulin sensitizer), 인슐린 감작제(insulin sensitizer), 나트륨 포도당 공동수송체(Sodium-glucose co-transporter 2 (SGLT2) inhibitor) 또는 디피피포 억제제(DPP-4 inhibitor))를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물에 관한 것이다.
PCT/KR2018/012392 2017-10-20 2018-10-19 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 WO2019078663A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/757,575 US11607441B2 (en) 2017-10-20 2018-10-19 Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
EP18867498.0A EP3698801A4 (en) 2017-10-20 2018-10-19 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES, WITH ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC MEDICINAL PRODUCT AS THE ACTIVE SUBSTANCES
CN201880068309.0A CN111246859B (zh) 2017-10-20 2018-10-19 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物
JP2020522310A JP7005050B2 (ja) 2017-10-20 2018-10-19 亜鉛塩、シクロ－ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0136242 2017-10-20
KR20170136242 2017-10-20

Publications (2)

Publication Number Publication Date
WO2019078663A2 WO2019078663A2 (ko) 2019-04-25
WO2019078663A3 true WO2019078663A3 (ko) 2019-06-06

Family

ID=66173406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012392 WO2019078663A2 (ko) 2017-10-20 2018-10-19 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물

Country Status (6)

Country Link
US (1) US11607441B2 (ko)
EP (1) EP3698801A4 (ko)
JP (1) JP7005050B2 (ko)
KR (1) KR102176069B1 (ko)
CN (1) CN111246859B (ko)
WO (1) WO2019078663A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345728A1 (en) * 2019-04-30 2020-11-05 Novmetapharma Co., Ltd. Compositions and methods for treatment of atherosclerosis
US11547737B2 (en) 2020-06-17 2023-01-10 Novmetapharma Co., Ltd. Compositions and methods for treating virus infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022786A (ko) * 1997-08-11 2001-03-26 문케이. 송 당뇨병 치료를 위한 방법 및 조성물
KR20060114600A (ko) * 2005-05-02 2006-11-07 주식회사 닥터엔팜 차가버섯 자실체로부터 추출한 신규의 항당뇨 활성 추출물및 이를 유효성분으로 함유한 항당뇨 활성 조성물
US20090123563A1 (en) * 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
KR20170021926A (ko) * 2013-07-05 2017-02-28 카딜라 핼쓰캐어 리미티드 상승적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1442741B1 (en) * 2003-01-31 2008-01-16 United States Government as represented by the Department of Veterans Affaires, At the Office of General Counsel - PSG IV (024) Compositions and methods for treating obesity
EP1962827A4 (en) * 2005-12-16 2011-02-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN
CN101674842A (zh) * 2007-03-02 2010-03-17 普瑞芬医药有限公司 治疗阿尔茨海默氏病和痴呆的组合物和方法
KR100910982B1 (ko) 2007-07-13 2009-08-05 바디텍메드 주식회사 당화헤모글로빈의 정량분석을 위한 시스템 및 이를 이용한당화헤모글로빈 측정 방법
US9062094B2 (en) * 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) * 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2012133693A1 (ja) * 2011-03-30 2012-10-04 キッセイ薬品工業株式会社 糖尿病治療用の組合せ医薬
US20170135981A1 (en) * 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
JP6553375B2 (ja) * 2014-06-24 2019-07-31 花王株式会社 Ｕｃｐ−１発現促進剤
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN106674230B (zh) * 2017-01-04 2019-07-02 陕西慧康生物科技有限责任公司 脯组环二肽的合成方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022786A (ko) * 1997-08-11 2001-03-26 문케이. 송 당뇨병 치료를 위한 방법 및 조성물
US20090123563A1 (en) * 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
KR20060114600A (ko) * 2005-05-02 2006-11-07 주식회사 닥터엔팜 차가버섯 자실체로부터 추출한 신규의 항당뇨 활성 추출물및 이를 유효성분으로 함유한 항당뇨 활성 조성물
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
KR20170021926A (ko) * 2013-07-05 2017-02-28 카딜라 핼쓰캐어 리미티드 상승적 조성물

Also Published As

Publication number Publication date
EP3698801A4 (en) 2021-07-21
JP2021500358A (ja) 2021-01-07
KR20190044559A (ko) 2019-04-30
US20200353034A1 (en) 2020-11-12
WO2019078663A2 (ko) 2019-04-25
US11607441B2 (en) 2023-03-21
EP3698801A2 (en) 2020-08-26
KR102176069B1 (ko) 2020-11-09
CN111246859B (zh) 2022-05-03
CN111246859A (zh) 2020-06-05
JP7005050B2 (ja) 2022-01-21

Similar Documents

Publication Publication Date Title
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
EP4269440A3 (en) Composition for treating il-6-related diseases
BRPI0606397A (pt) derivados de 1-tio-d-glucitol
EP4108242A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING A MTOR SIGNALING INHIBITOR AS ACTIVE INGREDIENT
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2021014680A (es) Derivado de benzotriazol.
MX2020012989A (es) Agente terapeutico para la fibrosis.
WO2019078663A3 (ko) 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
MX2022013588A (es) Combinación de fármacos para tratar la diabetes mellitus y sus complicaciones y composición farmacéutica de la combinación de fármacos.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EP3964520A4 (en) NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
EP4015042A4 (en) PHARMACEUTICAL COMPOSITION WITH ANTIFUNGAL AS AN ACTIVE SUBSTANCE
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
WO2018074880A3 (ko) 퀴놀린 4-온 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 폐렴의 예방 또는 치료용 약학적 조성물
PH12016502226A1 (en) Bicyclic derivatives and pharmaceutical composition including the same
MX2022003096A (es) Tratamiento de la diabetes mellitus tipo 2.
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION WITH A TSP1 PROTEIN INHIBITOR AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF FABRY DISEASE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867498

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020522310

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018867498

Country of ref document: EP

Effective date: 20200520